Anne Bendel

Dr. Anne Bendel


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ADAnirban Das
Anirban Das
SSSumedha Sudhaman
Sumedha Sudhaman
DMDaniel Morgenstern
Daniel Morgenstern
ACAilish Coblentz
Ailish Coblentz
JCJiil Chung
Jiil Chung
UTUri Tabori
Uri Tabori
Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading deficiency (MMRD and PPD) in children harbour the highest mutational and microsatellite insertion–deletion (MS-indel) burden in humans. MMRD and PPD cancers are commonly lethal due to the inherent resistance to chemo-irradiation. Although immune checkpoint inhibitors (ICIs) have failed to benefit children in previous studies, we hypothesized that hypermutation caused by MMRD and PPD will improve outcomes following ICI treatment in these patients. Using an international consortium registry study, we report on the ICI treatment of 45 progressive or recurrent tumors from 38 patients. Durable objective responses were observed in most patients, culminating in a 3 year survival of 41.4%. High mutation burden predicted response for ultra-hypermutant cancers (>100 mutations per Mb) enriched for combined MMRD + PPD, while MS-indels predicted response in MMRD tumors with lower mutation burden (10–100 mutations per Mb). Furthermore, both mechanisms were associated with increased immune infiltration even in ‘immunologically cold’ tumors such as gliomas, contributing to the favorable response. Pseudo-progression (flare) was common and was associated with immune activation in the tumor microenvironment and systemically. Furthermore, patients with flare who continued ICI treatment achieved durable responses. This study demonstrates improved survival for patients with tumors not previously known to respond to ICI treatment, including central nervous system and synchronous cancers, and identifies the dual roles of mutation burden and MS-indels in predicting sustained response to immunotherapy.

18 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SUSanthosh A. Upadhyaya
Santhosh A. Upadhyaya
GRGiles Robinson
Giles Robinson
AOArzu Onar-Thomas
Arzu Onar-Thomas
BOBrent Orr
Brent Orr
PJPascal Johann
Pascal Johann
AGAmar Gajjar
Amar Gajjar
Purpose: Report relevance of molecular groups to clinicopathologic features, germline SMARCB1/SMARCA4 alterations (GLA), and survival of children with atypical teratoid rhabdoid tumor (ATRT) treated in two multi-institutional clinical trials. Materials and Methods: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; n = 52) and children (SJMB03: age 3–21 years; n = 22), using surgery, conventional chemotherapy (infants), or dose-dense chemotherapy with autologous stem cell rescue (children), and age- and risk-adapted radiotherapy [focal (infants) and craniospinal (CSI; children)]. Molecular groups ATRT-MYC (MYC), ATRT-SHH (SHH), and ATRT-TYR (TYR) were determined from tumor DNA methylation profiles. Results: Twenty-four participants (32%) were alive at time of analysis at a median follow-up of 8.4 years (range, 3.1–14.1 years). Methylation profiling classified 64 ATRTs as TYR (n = 21), SHH (n = 30), and MYC (n = 13), SHH group being associated with metastatic disease. Among infants, TYR group had the best overall survival (OS; P = 0.02). However, outcomes did not differ by molecular groups among infants with nonmetastatic (M0) disease. Children with M0 disease and <1.5 cm2 residual tumor had a 5-year progression-free survival (PFS) of 72.7 ± 12.7% and OS of 81.8 ± 11%. Infants with M0 disease had a 5-year PFS of 39.1 ± 11.5% and OS of 51.8 ± 12%. Those with metastases fared poorly [5-year OS 25 ± 12.5% (children) and 0% (infants)]. SMARCB1 GLAs were not associated with PFS. Conclusions: Among infants, those with ATRT-TYR had the best OS. ATRT-SHH was associated with metastases and consequently with inferior outcomes. Children with nonmetastatic ATRT benefit from postoperative CSI and adjuvant chemotherapy.

28 January 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MEMoatasem El‐Ayadi
Moatasem El‐Ayadi
MAMarc Ansari
Marc Ansari
CKCaspar D. Kühnöl
Caspar D. Kühnöl
ABAnne Bendel
Anne Bendel
DSDominik Sturm
Dominik Sturm
Andre von BuerenAndre von Bueren
Andre von Bueren

3 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

17 June 2019 in Children
Verified
Journal Article
Open access
PDF file
MSMary Skrypek
Mary Skrypek
BBBruce Bostrom
Bruce Bostrom
ABAnne Bendel
Anne Bendel
In Minnesota, medical cannabis was approved for use in 2014. From July 2015 to February 2019, our center certified 103 pediatric and young adult patients for the use of medical cannabis under the qualifying conditions of cancer and treatment-related symptoms. Here, we provide a review of the literature on medical cannabis use in pediatric and young adult cancer patients. We also provide demographic data on our patients certified for medical cannabis. The most common diagnoses were leukemia/lymphoma (36%), brain tumors (37%), and malignant solid tumors (26%). The most common indications were chemotherapy-related nausea, pain, and cancer cachexia. The age range at certification was 1.4–28.7 years (median 15.3 years). The time from cancer diagnosis to certification ranged from 0.5–197 months (median 8.9 months). The majority (94%) were certified during their first line of treatment. In the 32 patients who died from recurrent or progressive cancer, the time from certification to death was 1.3–30.3 months (median 4.4 years). Despite requesting certification, a subset (24%) never had medical cannabis dispensed. In our experience, pediatric and young adult oncology patients are interested in medical cannabis to help manage treatment-related symptoms. Ongoing analysis of this data will identify the therapeutic efficacy of medical cannabis.

9 August 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CBCharles R. Bendelsmith
Charles R. Bendelsmith
MSMary M. Skrypek
Mary M. Skrypek
SPSachin R. Patel
Sachin R. Patel
DPDinel A. Pond
Dinel A. Pond
ALAmy M. Linabery
Amy M. Linabery
ABAnne Bendel
Anne Bendel